T.J. Craddick
Chief Scientific Officer HuidaGene Therapeutics
Seminars
Thursday 1st October 2026
Viral vs Non Viral Delivery: Opportunities to Improve Activity, Manufacturing & Regulatory Paths
1:00 pm
- The next evolution gene editing, gene writing and gene insertion have increased interest in evaluating viral and non‑viral delivery platforms, including evolving criteria around scalability, safety, and clinical applicability
- Key sources of manufacturing complexity and variability across modalities, and how these impact development timelines and operational models
- How the delivery landscape has evolved — and what this means for integrating mRNA and emerging approaches alongside established platforms
